Caffeine — Effects of Caffeine on EEG Theta/Beta Ratio and Cognitive Control
Citation(s)
Arnsten AF Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009 Jun;10(6):410-22. doi: 10.1038/nrn2648. Review.
Barry RJ, Clarke AR, Johnstone SJ A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. Clin Neurophysiol. 2003 Feb;114(2):171-83. Review.
Cools R, D'Esposito M Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry. 2011 Jun 15;69(12):e113-25. doi: 10.1016/j.biopsych.2011.03.028. Review.
Derryberry D, Reed MA Anxiety-related attentional biases and their regulation by attentional control. J Abnorm Psychol. 2002 May;111(2):225-36.
Einöther SJ, Giesbrecht T Caffeine as an attention enhancer: reviewing existing assumptions. Psychopharmacology (Berl). 2013 Jan;225(2):251-74. doi: 10.1007/s00213-012-2917-4. Review.
Putman P, van Peer J, Maimari I, van der Werff S EEG theta/beta ratio in relation to fear-modulated response-inhibition, attentional control, and affective traits. Biol Psychol. 2010 Feb;83(2):73-8. doi: 10.1016/j.biopsycho.2009.10.008.
Putman P, Verkuil B, Arias-Garcia E, Pantazi I, van Schie C EEG theta/beta ratio as a potential biomarker for attentional control and resilience against deleterious effects of stress on attention. Cogn Affect Behav Neurosci. 2014 Jun;14(2):782-91. doi: 10.3758/s13415-013-0238-7.
Smillie LD, Gökçen E Caffeine enhances working memory for extraverts. Biol Psychol. 2010 Dec;85(3):496-8. doi: 10.1016/j.biopsycho.2010.08.012.
The Effects of a Single Administration of a Moderate Dose of Caffeine on Cognitive Control and Spontaneous EEG Theta/Beta Ratio
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
